Compare Quest Diagnostics Inc (DGX) vs iShares MSCI France ETF (EWQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs iShares MSCI France ETF — how do they compare? Quest Diagnostics Inc trades at $202.3 (market cap $22.80B), while iShares MSCI France ETF trades at $45.41. The key difference: Quest Diagnostics Inc pays a 1.67% dividend while iShares MSCI France ETF pays none, and Quest Diagnostics Inc is trading nearer its 52-week high, iShares MSCI France ETF nearer its low. Which is the better fit depends on your goals.
| DGX | EWQ | |
|---|---|---|
Market Cap | $22.80B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $216.02 | $48.35 |
52-Week Low | $166.42 | $41.43 |
Enterprise Value | $28.82B | — |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
EWQ is currently trading at $44.83, down 0.47% on the day, with technical indicators showing a bearish trend as moving averages signal strong selling pressure. The stock faces resistance at $45 and support at $44, with oscillators remaining neutral. Recent corporate actions include a $1.09 dividend scheduled for payment in June 2026, providing income potential for long-term holders.
The outlook remains cautious due to technical weakness and European market volatility from ECB rate hikes and energy price pressures. Investment opportunity exists through dividend income, but risks include geopolitical tensions affecting European equities and potential short-squeeze volatility. The stock requires careful monitoring of European economic developments and technical breakout levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About iShares MSCI France ETF
EWQ is a country-specific ETF that tracks the performance of the French equity market. It provides exposure to major global brands across sectors like luxury goods, industrials, and healthcare, including LVMH, Schneider Electric, and Hermes.
Read more on EWQ →
